Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958299 | 0.90 | MAPK1 (0.36) | MAPK1CYP1A2ALDH1A1KDM4ERXFP1 | |
| SCHEMBL2972714 | 0.78 | CYP1A2 (0.35) | MAPK1CYP1A2POLBALDH1A1SLC6A2 | |
| SCHEMBL2962267 | 0.76 | MAPK1 (0.38) | MAPK1CYP1A2PGRTP53MAPT | |
| SCHEMBL2958732 | 0.76 | RAPGEF4 (0.33) | PGR | |
| SCHEMBL2964022 | 0.75 | ALDH1A1 (0.39) | MAPK1PGRMAPTALDH1A1KDM4E | |
| SCHEMBL2975584 | 0.75 | PBRM1 (0.36) | ALDH1A1 | |
| SCHEMBL2974296 | 0.74 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL2974937 | 0.72 | PGR (0.40) | MAPK1CYP1A2PGRALDH1A1SLC6A2 | |
| SCHEMBL2970025 | 0.71 | TP53 (0.35) | TP53POLBMAPTALDH1A1SLC6A2 | |
| SCHEMBL2972913 | 0.70 | MAPK1 (0.32) | MAPK1CYP1A2PGRTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | MAPK1 3118/4885CYP1A2 2409/4885PGR 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.